Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2017 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
OVID on Nasdaq
Shares outstanding
134,553,130
Price per share
$1.52
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
61,768,473
Total reported value
$100,169,419
% of total 13F portfolios
0%
Share change
+33,214,060
Value change
+$54,659,119
Number of holders
83
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% $19,889,602 13,259,735 RA Capital Management, L.P. 11 Dec 2025
Affinity Asset Advisors, LLC 9% 0% $19,803,141 12,149,166 0% Affinity Asset Advisors, LLC 22 Jan 2026
ADAR1 Capital Management, LLC 6.9% $14,111,932 9,284,166 ADAR1 Capital Management, LLC 31 Dec 2025
TAKEDA PHARMACEUTICAL CO LTD 12% $11,680,055 8,781,996 Takeda Pharmaceutical Company Limited 08 Dec 2025
FEDERATED HERMES, INC. 5.9% $12,611,581 7,737,166 Federated Hermes, Inc. 31 Dec 2025
JANUS HENDERSON GROUP PLC 10% $9,461,772 7,114,114 JANUS HENDERSON GROUP PLC 28 Nov 2025
Point72 Asset Management, L.P. 5.1% $11,099,895 6,727,209 Point72 Asset Management, L.P. 02 Jan 2026
Madison Avenue Partners, LP 4% $969,800 2,852,352 Madison Avenue Partners, LP 31 Dec 2024
BlackRock, Inc. 1.9% $451,636 1,369,010 BlackRock, Inc. 30 Jun 2025
Rubric Capital Management LP 0.67% $153,131 478,533 Rubric Capital Management LP 30 Jun 2025

As of 31 Dec 2025, 83 institutional investors reported holding 61,768,473 shares of Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID). This represents 46% of the company’s total 134,553,130 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID) together control 43% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 8% 10,714,000 0.18% $17,463,820
Affinity Asset Advisors, LLC 5.3% 7,150,000 +170% 0.84% $11,654,500
ADAR1 Capital Management, LLC 3.2% 4,285,000 +33257% 0.52% $6,984,550
EVENTIDE ASSET MANAGEMENT, LLC 3.2% 4,285,000 0.11% $6,984,550
FEDERATED HERMES, INC. 2.7% 3,571,000 0.01% $5,306,813
Point72 Asset Management, L.P. 2.6% 3,551,129 0.01% $5,788,340
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.6% 3,492,000 +159% 0.01% $5,691,960
VANGUARD GROUP INC 2.3% 3,072,227 +8.9% 0% $5,007,730
Saturn V Capital Management LP 1.9% 2,500,000 0.75% $4,075,000
Ally Bridge Group (NY) LLC 1.3% 1,785,000 4.6% $2,909,550
RENAISSANCE TECHNOLOGIES LLC 1.1% 1,484,478 -26% 0% $2,419,699
Sio Capital Management, LLC 1.1% 1,427,495 0% 0.39% $2,326,817
MILLENNIUM MANAGEMENT LLC 1% 1,339,465 +36% 0% $2,183,328
MARSHALL WACE, LLP 0.94% 1,271,487 +62% 0% $2,072,525
ACADIAN ASSET MANAGEMENT LLC 0.92% 1,231,698 -46% 0% $2,007,000
AWM Investment Company, Inc. 0.67% 899,200 0.14% $1,465,696
JANE STREET GROUP, LLC 0.66% 883,867 +271% 0% $1,440,704
CITADEL ADVISORS LLC 0.59% 797,824 +97% 0% $1,300,453
WELLS FARGO & COMPANY/MN 0.54% 720,848 -1.4% 0% $1,174,983
GEODE CAPITAL MANAGEMENT, LLC 0.5% 672,004 +3.7% 0% $1,095,612
Assenagon Asset Management S.A. 0.46% 618,019 -33% 0% $1,007,371
BlackRock, Inc. 0.46% 613,475 +0.35% 0% $999,964
TWO SIGMA INVESTMENTS, LP 0.45% 598,869 +76% 0% $976,156
Walleye Capital LLC 0.39% 530,020 -11% 0% $863,933
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.25% 341,740 -42% 0% $557,036

Institutional Holders of Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 61,768,473 $100,169,419 +$54,659,119 $1.63 83
2025 Q3 36,211,271 $47,075,130 +$6,613,804 $1.30 80
2025 Q2 35,963,686 $11,861,338 -$3,392,024 $0.33 69
2025 Q1 46,399,305 $14,469,971 -$2,823,886 $0.31 81
2024 Q4 47,565,663 $44,391,185 +$933,718 $0.93 80
2024 Q3 46,326,650 $54,661,169 -$2,312,497 $1.18 75
2024 Q2 46,022,725 $35,395,023 -$20,868,716 $0.77 72
2024 Q1 50,111,416 $152,838,625 -$4,734,653 $3.05 80
2023 Q4 51,658,816 $166,339,097 +$8,163,314 $3.22 77
2023 Q3 42,343,665 $162,598,117 +$5,682,119 $3.84 64
2023 Q2 41,007,449 $134,502,613 +$8,714,482 $3.28 69
2023 Q1 38,694,424 $99,783,463 +$651,350 $2.58 60
2022 Q4 38,559,195 $71,717,529 +$2,582,813 $1.86 58
2022 Q3 35,588,862 $65,480,293 +$1,720,712 $1.84 55
2022 Q2 34,628,854 $74,450,307 -$3,009,412 $2.15 52
2022 Q1 35,130,112 $110,307,198 +$3,432,314 $3.14 61
2021 Q4 34,014,426 $109,179,202 +$1,236,530 $3.21 65
2021 Q3 33,589,442 $112,862,212 -$90,780 $3.36 70
2021 Q2 33,366,478 $130,460,427 -$11,009,099 $3.91 76
2021 Q1 36,251,183 $145,725,613 +$42,574,480 $4.02 85
2020 Q4 27,412,279 $63,321,129 -$6,383,233 $2.31 75
2020 Q3 25,114,493 $144,162,828 +$11,138,040 $5.74 90
2020 Q2 21,848,899 $161,034,711 +$48,530,099 $7.37 78
2020 Q1 15,867,223 $47,289,209 -$7,210,519 $2.98 56
2019 Q4 17,761,607 $73,712,290 +$38,255,959 $4.15 58
2019 Q3 8,206,512 $26,588,025 -$5,121,377 $3.24 37
2019 Q2 10,120,957 $18,724,869 -$3,707,140 $1.85 33
2019 Q1 12,276,773 $21,734,954 +$9,093,088 $1.77 47
2018 Q4 6,835,729 $16,540,605 -$8,205,077 $2.42 46
2018 Q3 7,393,156 $41,919,393 -$3,040,105 $5.67 49
2018 Q2 7,653,221 $59,692,116 +$4,811,013 $7.80 47
2018 Q1 7,048,747 $49,828,303 -$9,279,532 $7.07 48
2017 Q4 7,822,508 $77,212,294 +$5,977,174 $9.87 49
2017 Q3 7,221,932 $61,486,225 -$7,070,486 $8.57 42
2017 Q2 7,991,379 $81,779,560 +$81,779,559 $10.49 43